| Upland Grove Medical Group | |
|
1330 San Bernardino Rd Suite B Upland CA 91786-4928 | |
| (909) 981-0608 | |
| (866) 695-1267 |
| Full Name | Upland Grove Medical Group |
|---|---|
| Speciality | Pain Medicine |
| Location | 1330 San Bernardino Rd, Upland, California |
| Authorized Official Name and Position | Gregory K. Suelzle (OWNER) |
| Authorized Official Contact | 9099810608 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Upland Grove Medical Group 1330 San Bernardino Rd Suite B Upland CA 91786-4928 Ph: (909) 981-0608 | Upland Grove Medical Group 1330 San Bernardino Rd Suite B Upland CA 91786-4928 Ph: (909) 981-0608 |
| NPI Number | 1386890044 |
|---|---|
| Provider Enumeration Date | 08/13/2008 |
| Last Update Date | 04/21/2014 |
| Medicare PECOS PAC ID | 2365598562 |
|---|---|
| Medicare Enrollment ID | O20090912000079 |
News Archive
Innovators at Purdue University have received new support as they work to develop solutions to what U.S. military officials call an alarming trend in dementia among wounded soldiers. The same researchers also seek solutions to better treat Alzheimer's disease.
A team of researchers at the University of Central Florida is using breakthrough gene-editing technology to develop a new screening tool for Parkinson's disease, a debilitating degenerative disorder of the nervous system.
One of the earliest events that changes a normal cell into a malignant one is known as deoxyribonucleic acid (DNA) hypermethylation, a biochemical alteration that inactivates critical tumor-suppressor genes.
TheraQuest Biosciences, Inc. a development stage pain management company today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug ("IND") application for TQ-1015, its abuse deterrent extended release strong opioid. TQ-1015 is being developed using Securel, TheraQuest's proprietary abuse deterrent technology.
› Verified 5 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386890044 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | G78385 (California) | Secondary |
| 208VP0014X | Pain Medicine - Interventional Pain Medicine | G77184 (California) | Primary |
| Provider Name | Gregory K Suelzle |
|---|---|
| Provider Type | Practitioner - Interventional Pain Management |
| Provider Identifiers | NPI Number: 1326016023 PECOS PAC ID: 2466344221 Enrollment ID: I20040326000488 |
News Archive
Innovators at Purdue University have received new support as they work to develop solutions to what U.S. military officials call an alarming trend in dementia among wounded soldiers. The same researchers also seek solutions to better treat Alzheimer's disease.
A team of researchers at the University of Central Florida is using breakthrough gene-editing technology to develop a new screening tool for Parkinson's disease, a debilitating degenerative disorder of the nervous system.
One of the earliest events that changes a normal cell into a malignant one is known as deoxyribonucleic acid (DNA) hypermethylation, a biochemical alteration that inactivates critical tumor-suppressor genes.
TheraQuest Biosciences, Inc. a development stage pain management company today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug ("IND") application for TQ-1015, its abuse deterrent extended release strong opioid. TQ-1015 is being developed using Securel, TheraQuest's proprietary abuse deterrent technology.
› Verified 5 days ago
News Archive
Innovators at Purdue University have received new support as they work to develop solutions to what U.S. military officials call an alarming trend in dementia among wounded soldiers. The same researchers also seek solutions to better treat Alzheimer's disease.
A team of researchers at the University of Central Florida is using breakthrough gene-editing technology to develop a new screening tool for Parkinson's disease, a debilitating degenerative disorder of the nervous system.
One of the earliest events that changes a normal cell into a malignant one is known as deoxyribonucleic acid (DNA) hypermethylation, a biochemical alteration that inactivates critical tumor-suppressor genes.
TheraQuest Biosciences, Inc. a development stage pain management company today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug ("IND") application for TQ-1015, its abuse deterrent extended release strong opioid. TQ-1015 is being developed using Securel, TheraQuest's proprietary abuse deterrent technology.
› Verified 5 days ago
John J Kim Md Inc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 629 N 13th Ave, Upland, CA 91786 Phone: 909-981-8905 Fax: 909-982-8051 | |
Upland Medical Center Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 308 N 2nd Ave, Upland, CA 91786 Phone: 909-920-9193 Fax: 909-920-6019 | |
Inland Empire Medical Network,inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 585 N Mountain Ave, Suite C, Upland, CA 91786 Phone: 909-981-8599 Fax: 909-981-5441 | |
Basim Z. Abdelkarim, M.d., Inc. Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1310 San Bernardino Rd Ste 103, Upland, CA 91786 Phone: 909-920-0444 Fax: 909-920-5044 | |
Edge Family Medicine Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 440 N Mountain Ave Ste 110, Upland, CA 91786 Phone: 909-870-5200 Fax: 909-870-5188 | |
Karnavy Medical Group, Inc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 300 E 7th St, Ste. 2e, Upland, CA 91786 Phone: 909-982-8976 Fax: 909-920-3176 | |
Generoso S Nery M D Inc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1183 E Foothill Blvd, Suite 135, Upland, CA 91786 Phone: 909-931-1368 Fax: 909-931-1372 |